Mineralocorticoid receptor antagonists (MRAs) are a cornerstone of evidence-based therapy for heart failure with reduced ejection fraction (HFrEF) [1,3,4], with a significant effect on adverse cardiac remodeling [5]. The gene discussed is NR3C2; the disease is heart failure.